-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study
(2439) Views (355) Full article downloads
Authors: Roland Asmar, Sophie Nisse-Durgeat
Published Date January 2006
Volume 2006:2(3) Pages 317 - 323
DOI: http://dx.doi.org/10.2147/VHRM.S
Roland Asmar1, Sophie Nisse-Durgeat2
1The Cardiovascular Institute, Paris, France; 2Laboratoire Takeda, Puteaux, France
Abstract: This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8–16 mg) in elderly (>65 years) hypertensive patients. Patients (n=3013) received CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if blood pressure remained uncontrolled (>140/90 mmHg). At week 8, 65.5% of patients were normalized (BP <140/90 mmHg). Mean changes at week 8 were –25.8, –13.2, and –12.7 mmHg for systolic, diastolic, and pulse pressure, respectively. Age, sex, and diabetic status did not influence the antihypertensive effect of CC. 68% of the patients treated with, but uncontrolled or intolerant of, prior antihypertensive treatment were normalized by CC 8–16 mg. In summary, CC 8– 16 mg once daily was effective and well tolerated in the management of arterial hypertension in elderly subjects.
Keywords: candesartan cilexetil, angiotensin II receptor antagonist, hypertension, elderly subject, CHANCE study
Readers of this article also read:
Metabolic syndrome: the danger signal in atherosclerosis
Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment
Insulin resistance and plasma triglyceride level are differently related to cardiac hypertrophy and arterial stiffening in hypertensive subjects
Erratum
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




